Inter Medico will distribute several EraGen molecular tests that recently received Health Canada approval for marketing as in vitro diagnostics.
The approved tests are performed on the company’s MultiCode RTx real-time PCR system. The system simplifies and enhances traditional real-time PCR, providing workflow, time-to-result, and flexibility benefits to clinicians and laboratories.
Irene Hrusovsky, president and CEO of EraGen, said: “EraGen’s entry into the Canadian market commences our planned expansion into lucrative, rapidly-growing molecular diagnostics markets outside of the US. We expect to seek Health Canada approval for additional EraGen tests and will bring them to market through Inter Medico upon approval.”